About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Research on MRSA Drug Halted by Novartis After Poor Tests

by Rajashri on August 30, 2008 at 2:30 PM
 Research on MRSA Drug Halted by Novartis After Poor Tests

Research into Novartis' Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug is being halted by the company after disappointing clinical tests.

The Swiss pharmaceutical giant said in a statement that it had decided to halt the programme "after Phase II results showed a lack of efficacy as an add-on therapy for life-threatening bacterial infections."

Advertisement

Novartis will take an impairment charge of 235 million dollars (159 million euros) in the third quarter as a result.

MRSA has shot to prominence in recent years as many people catch the bug while being treated in hospitals -- leading to doctors in Britain being banned from wearing their traditional white coats in favour of plastic aprons in a bid to reduce the risks of transmission.
Advertisement

Last June, the European Centre for Disease Prevention and Control (ECDC) warned that "healthcare-associated infections" such as MRSA, which are resistant to many antibiotics, are "possibly the biggest infectious disease challenge facing the EU."

It said that around three million people in the European Union catch a healthcare-associated infection every year and approximately 50,000 die as a result.

Source: AFP
RAS/L
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

WHO Approves R21/Matrix-M, the World's Second Malaria Vaccine
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
New Inverse Vaccine Sparks Hope in Diabetes, Arthritis, and Crohn's Disease
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Research on MRSA Drug Halted by Novartis After Poor Tests Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests